Theodore Pollock, DO
Hematology & Oncology · Grove City, OHNPI 1609817246
Payments from drug & device makers
Across 180 payments — averaging $5134.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$791K
- United Therapeutics Corporation$116K
- Eli Lilly$12K
- Incyte Corporation$4K
- E.r. Squibb & Sons, L.L.C.$502
- AstraZeneca$203
- plus $1K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 51 | $791,379 |
| United Therapeutics Corporation | 12 | $115,776 |
| Eli Lilly | 1 | $11,564 |
| Incyte Corporation | 26 | $3,503 |
| E.r. Squibb & Sons, L.L.C. | 15 | $502 |
| AstraZeneca | 9 | $203 |
| Spectrum Pharmaceuticals Inc. | 1 | $150 |
| Novartis | 8 | $138 |
| Genentech USA, Inc. | 8 | $124 |
| Pfizer | 8 | $121 |
| Astellas Pharma US Inc | 6 | $99 |
| Johnson & Johnson | 4 | $71 |
| Sanofi | 3 | $59 |
| EMD Serono, Inc. | 3 | $49 |
| Puma Biotechnology, Inc. | 3 | $42 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Lilly USA, LLC | 2 | $38 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $37 |
| Amgen | 2 | $33 |
| Bristol Myers Squibb | 2 | $32 |
| Gilead | 2 | $30 |
| Array Biopharma Inc | 2 | $28 |
| Boehringer Ingelheim | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Bayer | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Janssen Scientific Affairs, LLC | 1 | $13 |
How this compares
$924,153 in reported general payments places this provider in the 85th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Grove City
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.